October 25, 2024- Baxter recently reported that the company anticipates restarting the highest-throughput IV solutions manufacturing line within the next week, barring any unanticipated developments.
Initial batches will be manufactured concurrently with ongoing quality activities and will only be released in accordance with applicable regulatory requirements to ensure the quality and safety of the products. It is important to note that the earliest that new North Cove product could begin entering the distribution channel is mid- to late-November. This is, however, ahead of Baxter’s original expectations and is a testament to the urgency, diligence and resiliency of the North Cove and broader Baxter teams. Baxter has worked with the support of the FDA, ASPR, and HHS, and does not yet have a timeline for when it expects the North Cove production to be fully restored to pre-hurricane levels.
Continue Reading updates from Baxter.